GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 Notes to the Standalone Financial Statements for the year ended March 31, 2022 162 (ii) Details relating to parties referred to in items 1(i) , 1(ii) and 1 (iii) above: ( ` in lakhs) Holding Group/ultimate holding Group 1(i) Subsidiary of the company 1(ii) Other companies in the GSK Group 1(iii) Year ended March 31, 2022 Year ended March 31, 2021 Year ended March 31, 2022 Year ended March 31, 2021 Year ended March 31, 2022 Year ended March 31, 2021 1 Purchase of materials/traded goods - - 7,88.19 3,62.48 432,62.26 619,20.62 2 Sale of materials/sale of products (Refer Note 55) - - - - 65.19 63.17 3 Purchase of Vaccines business (Refer Note 57) - - - - 1,66.00 - 4 Purchase of license - - - - 8,99.82 - 5 Sale of brands and other identified assets (Refer Note 55) - - - - 1639,84.36 - 6 Expenses recharged to other companies - - 73.71 29.89 15,95.30 26,95.55 7 Expenses recharged by other companies 7.50 49.56 - - 144,43.40 96,35.07 8 Manufacturing charges recovered - - 15,16.15 4,65.95 - 4,31.95 9 Clinical research and data management recoveries - - - - 6,20.36 9,36.45 10 Interest income on loan given - - 44.80 - 3,19.58 - 11 Loans given - - 14,60.00 - 190,00.00 - 12 Liabilities written back - - - - - 77.24 13 Employee benefit liabilities transferred to a related party - - - - - 19.86 14 Loan receivable from related party - - 14,60.00 - 190,00.00 - 15 Outstanding receivables at the period end - - 4,74.68 4,04.06 41,86.64 7,29.68 16 Outstanding payables at the period end - 46.17 - - 116,65.46 118,94.44 17 Cross charges recoverable at the period end - - - - 8,50.00 4.82 (iii) Disclosure in respect of material transactions with parties referred to in item 1 (i) , 1(ii) and 1(iii) above: ( ` in lakhs) Year ended March 31, 2022 Year ended March 31, 2021 (a) Purchase of materials/traded goods: GlaxoSmithKline Asia Private Limited, India - 1,80.74 GlaxoSmithKline Biologicals S.A., Belgium 329,92.43 540,30.11 Biddle Sawyer Limited 7,88.19 3,62.48 GlaxoSmithKline Pharma India Pvt. Ltd. 15,53.70 10,51.03 GlaxoSmithKline Export Limited, U.K. 87,16.13 66,58.74 (b) Sale of materials/sale of products: GlaxoSmithKline Trading Services Limited, Ireland - 63.17 GlaxoSmithKline Asia Private Limited, India (Refer Note 55) 65.19 -